---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-277580"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:17:16.429761+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Enliven Q3 net loss $20.1M; cash $477.6M; Phase 1b enrollment completed for ELVN-001

## Summary
- Net loss $20.1M in Q3 2025 vs $23.2M in Q3 2024; R&D expenses $18.2M vs $21.3M.
- Cash, cash equivalents and marketable securities $477.6M; runway into first half 2029.
- Completed randomized Phase 1b portion of ENABLE trial evaluating ELVN-001 in CML patients.
- On track to initiate Phase 3 pivotal trial for ELVN-001 in 2026.
- Data from ELVN-001 in CML patients with atypical fusion transcripts to be presented at ASH 2025.

## SEC filing metadata
- accession: 0001193125-25-277580
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000119312525277580/0001193125-25-277580-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000119312525277580/elvn-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-277580
- JSON: https://secwatch.observer/filing/0001193125-25-277580.json
- Plain text: https://secwatch.observer/filing/0001193125-25-277580.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.